R36
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 65
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.630
- INTERFERON_GAMMA_RESPONSE+0.460
- WNT_BETA_CATENIN_SIGNALING+0.400
- ALLOGRAFT_REJECTION+0.350
- CHOLESTEROL_HOMEOSTASIS+0.260
- DNA_REPAIR+0.260
- GLYCOLYSIS+0.240
- HYPOXIA+0.230
- IL6_JAK_STAT3_SIGNALING+0.220
- APOPTOSIS+0.210
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.320
- UV_RESPONSE_DN-0.310
- KRAS_SIGNALING_UP-0.220
- NOTCH_SIGNALING-0.190
- PROTEIN_SECRETION-0.180
- ANDROGEN_RESPONSE-0.170
- ADIPOGENESIS-0.150
- BILE_ACID_METABOLISM-0.130
- PEROXISOME-0.130
- XENOBIOTIC_METABOLISM-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208966 | — | — | 0.758 |
| 2 | SRR8613750 | — | D | 0.739 |
| 3 | R178 | — | — | 0.721 |
| 4 | SJEPD034_D.RNA-Seq | EPN | Supratentorial EPN | 0.691 |
| 5 | TCGA-A7-A4SD-01A-11R-A266-07 | — | E | 0.689 |
| 6 | TCGA-E2-A573-01A-11R-A29R-07 | — | E | 0.687 |
| 7 | DRR168610 | — | — | 0.683 |
| 8 | TCGA-E9-A3QA-01A-61R-A22K-07 | — | D | 0.672 |
| 9 | TCGA-05-4398-01A-01R-1206-07 | — | cohortA1 | 0.672 |
| 10 | MNG1088 | — | — | 0.658 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.630 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.460 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.260 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| HYPOXIA | 0.230 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.170 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.170 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.150 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.110 | Idelalisib | — uncovered |